Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -60.79% is 16% below its 5-year average of -52.22%, around the middle of its 5-year range (-117.97%–-28.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.55% above its 12-month average of -78.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -60.79%.
RETURN ON EQUITY (ROE)
-60.79%
RETURN ON EQUITY (ROE) AVG TTM
-78.49%
RETURN ON EQUITY (ROE) AVG 3Y
-67.89%
RETURN ON EQUITY (ROE) AVG 5Y
-52.22%
RETURN ON EQUITY (ROE) AVG 10Y
-59.94%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.55%
CURRENT VS 3Y AVG
+10.46%
CURRENT VS 5Y AVG
-16.41%
CURRENT VS 10Y AVG
-1.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-68.85%
vs the sector median at left
Aclaris Therapeutics, Inc.
Market Cap
$596.36M
Return on Equity (ROE)
-60.79%
TTM Avg
-78.49%
3Y Avg
-67.89%
5Y Avg
-52.22%
Market Cap
$579.88M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$573.38M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$569.56M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$561.67M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$632.76M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$637.59M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$551.09M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$642.31M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $596.36M | -60.79% | -78.49% | -67.89% | -52.22% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | N/A | 44.05% | 44.05% | 44.05% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 161.13% | 93.89% | 96.07% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 40.62% | 9.52% | -25.24% | -32.61% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -24.06% | -36.09% | -34.99% | -44.03% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -8.42% | -4.61% | -3.17% | 11.46% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -17.44% | -97.25% | -87.77% | -77.06% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -21.51% | -20.05% | -35.91% | -26.18% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -41.56% | -67.38% | -49.66% | -56.07% |
ROE
-60.8%
ROA
-42.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -60.79% |
| 2026-03-31 | -48.49% |
| 2025-12-31 | -62.98% |
| 2025-09-30 | -117.97% |
| 2025-06-30 | -102.21% |
| 2025-03-31 | -90.38% |
| 2024-12-31 | -84.90% |
| 2024-09-30 | -28.43% |
| 2024-06-30 | -43.85% |
| 2024-03-31 | -54.40% |
| 2023-12-31 | -56.29% |
| 2023-09-30 | -73.32% |
| 2023-06-30 | -58.59% |
| 2023-03-31 | -54.45% |
| 2022-12-31 | -43.98% |
| 2022-09-30 | -37.34% |
| 2022-06-30 | -35.32% |
| 2022-03-31 | -44.89% |
| 2021-12-31 | -46.04% |
| 2021-09-30 | -37.51% |
| 2021-06-30 | -30.26% |
| 2021-03-31 | -57.16% |
| 2020-12-31 | -135.50% |
| 2020-09-30 | -138.47% |
| 2020-06-30 | -204.79% |
| 2020-03-31 | -239.58% |
| 2019-12-31 | -230.80% |
| 2019-09-30 | -212.62% |
| 2019-06-30 | -115.67% |
| 2019-03-31 | -76.86% |
| 2018-12-31 | -61.70% |
| 2018-09-30 | -80.04% |
| 2018-06-30 | -58.88% |
| 2018-03-31 | -43.00% |
| 2017-12-31 | -30.42% |
| 2017-09-30 | -23.36% |
| 2017-06-30 | -29.48% |
| 2017-03-31 | -29.70% |
| 2016-12-31 | -28.37% |
| 2016-09-30 | -50.93% |
| 2016-06-30 | -45.72% |
| 2016-03-31 | -37.23% |
| 2015-12-31 | -22.23% |
| 2015-06-30 | -96.99% |
| 2015-03-31 | -62.59% |
